Biotech company Advanced Enzyme Technologies Limited acquired evoxx technologies GmbH, a German industrial biotechnology company.
evoxx and its team of 35+ scientists & technicians across the two sites in Germany, Monheim am Rhein and Potsdam, will be the Research & Development centers and sales points of Advanced Enzymes in Europe. The acquisition will also help Advanced Enzymes expand its enzyme portfolio & business in biocatalysis and food applications.
Following the acquisition, evoxx will ensure continuity in cooperative projects with customers and partners. Its proprietary technology platform which enables development of tailor-made enzymes and processes for various industries will be still available in the future.
Led by Dr. Thorsten Eggert, CEO, evoxx technologies is focusing on the development and production of industrial enzymes and novel carbohydrate ingredients produced by enzymatic bioconversion. With its proprietary enzymes and carbohydrate ingredients, the company is active in high growth markets addressing consumer needs in the global food health & wellness sector and consumer products markets. Product development is based on the proprietary technology and patent platform covering the whole value chain from early enzyme and process development to industrial scale production and product deregulation.
It was an HTGF portfolio company.
Incorporated in 1989, Advanced Enzyme Technologies is a research driven company with global leadership in the manufacturing of enzymes. Equipped with 7 manufacturing facilities and 5 research & development centres across India and US, the company exports to 45+ countries across 6 continents.
FinSMEs
04/08/2017